iLIVER最新文献

{"title":"Arginine methylation modification in the malignant progression of benign and malignant liver diseases","authors":"Jie-Zuo Huang ,&nbsp;Bei-Ning Qiao ,&nbsp;Dang-Chi Li ,&nbsp;Qiu-Rong Wei ,&nbsp;Zi-Jian Zhang","doi":"10.1016/j.iliver.2024.100124","DOIUrl":"10.1016/j.iliver.2024.100124","url":null,"abstract":"<div><div>The role of protein arginine methyltransferases (PRMTs) in benign and malignant liver diseases has garnered considerable attention. PRMTs play a key function in regulating protein methylation modification in diseases such as alcoholic fatty liver disease, metabolic dysfunction–associated steatotic liver disease, viral hepatitis, and hepatocellular carcinoma. This review explores the mechanisms of action of PRMTs in these diseases, with a focus on their effects on cell signaling, transcriptional regulation, cell proliferation, and metabolism. We also discuss potential therapeutic strategies targeting PRMTs and propose future research directions. This review helps deepen the understanding of the important role of arginine methylation modification in the malignant progression of liver diseases and provides guidance for future clinical treatment and drug development.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 4","pages":"Article 100124"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142528996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Full robotic whole graft liver transplantation: Is a new era coming?","authors":"Yipeng Pan ,&nbsp;Jimin Liu ,&nbsp;Qi Ling","doi":"10.1016/j.iliver.2024.100128","DOIUrl":"10.1016/j.iliver.2024.100128","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 4","pages":"Article 100128"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142748569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Danning tablets for the treatment of multiple gallbladder polyps: Study protocol of multicentre, randomised, open-labelled, controlled trial","authors":"Tian Yang ,&nbsp;Ming-Da Wang ,&nbsp;Gui-Lin Xie ,&nbsp;Xiong-Hua Wang ,&nbsp;Liu Zheng ,&nbsp;Li-Min Wang ,&nbsp;Guang-Fa Xiao ,&nbsp;Yong-Qing Yang ,&nbsp;Chao Li ,&nbsp;Alfred Wei Chieh Kow ,&nbsp;Feng Shen","doi":"10.1016/j.iliver.2024.100127","DOIUrl":"10.1016/j.iliver.2024.100127","url":null,"abstract":"<div><h3>Introduction</h3><div>Gallbladder polyps (GPs) are protrusions of the gallbladder wall into the lumen, and are commonly detected during ultrasound examinations. Traditional management of multiple GPs (MGPs) has been conservative, including lifestyle interventions, regular monitoring, and surgical intervention in certain cases, but this approach poses risks of polyps enlargement and increase of number, as well as patients’ psychological burdens. Danning Tablets, a traditional Chinese medicine, have emerged as a potential non-surgical treatment for GPs, showing promise in reducing polyp size and alleviating symptoms, backed by their anti-inflammatory and antitumor properties demonstrated in preclinical studies. This suggests the need for further research into Danning Tablets as an alternative treatment for MGPs.</div></div><div><h3>Methods and analysis</h3><div>The study is designed as a prospective, randomized, controlled, open-label trial. The study will be conducted across multiple centres specializing in gastroenterology and hepatology. Participants will be recruited from these centres, ensuring a diverse patient demographic. Adult patients diagnosed with MGPs, based on ultrasound findings, will be included. Exclusion criteria include patients with a history of gallbladder cancer, previous gallbladder surgery, or serious comorbid conditions. The control group will receive standard care, including dietary and lifestyle advice, while the intervention group will receive Danning Tablets and standard care. The dosage and administration of Danning Tablets will follow established clinical guidelines. The primary outcome will be the change in size of the largest gallbladder polyps on week 24 ± 1, measured by ultrasound. The secondary outcomes will include symptom improvement and recording of any adverse events. The study will span over a period of 6 months, with periodic assessments at baseline, 4, 8, 12, and 24 weeks.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 4","pages":"Article 100127"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142706991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Dr. Sun et al.: Female DILI patients need more clinical attention","authors":"Yu-Ting Xiong,&nbsp;Chun-Yan Wang,&nbsp;Dong Ji","doi":"10.1016/j.iliver.2024.100126","DOIUrl":"10.1016/j.iliver.2024.100126","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 4","pages":"Article 100126"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142706993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic treatment in unresectable hepatocellular carcinoma: The most concerns","authors":"Jian-Hong Zhong,&nbsp;Kang Chen,&nbsp;Ze Su,&nbsp;Shao-Ping Liu,&nbsp;Fan-Jian Zeng,&nbsp;Lin Ye,&nbsp;the GUIDANCE investigators","doi":"10.1016/j.iliver.2024.100112","DOIUrl":"10.1016/j.iliver.2024.100112","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 3","pages":"Article 100112"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000379/pdfft?md5=520af061d7f9f40ec565cf72ac9acec5&pid=1-s2.0-S2772947824000379-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142076358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short-term effects of modified ultrasonography in laparoscopic anatomical hepatectomy for hepatocellular carcinoma","authors":"Xun Wang ,&nbsp;Xuan Meng ,&nbsp;Liming Wang,&nbsp;Peng Wang,&nbsp;Zhihao Wang,&nbsp;Weiqi Rong,&nbsp;Zhiyu Lu,&nbsp;Hongguang Wang","doi":"10.1016/j.iliver.2024.100106","DOIUrl":"10.1016/j.iliver.2024.100106","url":null,"abstract":"<div><h3>Background and aims</h3><p>Laparoscopic hepatectomy is challenging, and ultrasound guidance is an effective aid but lacks standardization. This study aimed to evaluate a modified approach for laparoscopic ultrasonography to enhance surgical outcomes.</p></div><div><h3>Methods</h3><p>Between January 2020 and August 2023, 122 patients who underwent real-time ultrasound-guided laparoscopic anatomical hepatectomy for hepatocellular carcinoma were enrolled and divided into modified and traditional ultrasonography groups. The modified ultrasound application comprised intraoperative protocol-based laparoscopic ultrasonography comprising application scenarios; standardized positions for the surgeon, trocar, and probe; and the resulting standardized sections for various laparoscopic liver resections. Clinical characteristics and perioperative outcomes were compared between the two groups. Subgroup analysis was performed and comprised techniques for modified duct structure identification and portal vein branch puncture; both techniques were used in fluorescence probe-mounted laparoscopic liver resection using negative and positive staining procedures, respectively.</p></div><div><h3>Results</h3><p>The traditional and modified groups comprised 64 and 58 patients, respectively. The patients’ background characteristics were not significantly different between the groups. Surgical duration (283.4 min vs. 225.1 min; <em>p</em> &lt; 0.001), Pringle maneuver duration (47.4 min vs. 39.5 min; <em>p</em> = 0.014), bleeding volume (258.6 mL vs. 174.8 mL; <em>p</em> = 0.005), overall complication rate (31.3% vs. 15.5%; <em>p</em> = 0.041), and postoperative stay were significantly greater in the traditional vs. modified ultrasonography groups, respectively. The modified method positively affected the number of punctures, success rate of staining, intraoperative bleeding volume, and operation duration.</p></div><div><h3>Conclusions</h3><p>Modified ultrasonography improves the safety and effectiveness of laparoscopic hepatectomy. Ultrasonography is pivotal, especially in fluorescence probe-assisted laparoscopic liver resection.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 3","pages":"Article 100106"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000318/pdfft?md5=be0303c5aa9e5b1f82a1533c9b8ebe58&pid=1-s2.0-S2772947824000318-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141708607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Network pharmacology and single-cell transcriptomic analysis with molecular docking to elucidate the potential compounds and targets of Polygonum cuspidatum Sieb.et Zucc. for hepatocellular carcinoma","authors":"Wenze Wu ,&nbsp;Yuzhu Shi ,&nbsp;Yongzi Wu ,&nbsp;Rui Zhang ,&nbsp;Xinyan Wu ,&nbsp;Weidi Zhao ,&nbsp;Zhiyuan Chen ,&nbsp;Gang Ye","doi":"10.1016/j.iliver.2024.100115","DOIUrl":"10.1016/j.iliver.2024.100115","url":null,"abstract":"<div><h3>Background and aims</h3><p><em>Polygonum cuspidatum</em> Sieb.et Zucc. (<em>P. cuspidatum</em>) and its active components have been clinically proven to have anti-hepatocellular carcinoma effects. However, the potential targets of <em>P. cuspidatum</em> for these effects have not yet been revealed.</p></div><div><h3>Methods</h3><p>We used network pharmacology and single-cell transcriptomic analysis with molecular docking to elucidate the active components and targets of <em>P. cuspidatum</em> for hepatocellular carcinoma.</p></div><div><h3>Results</h3><p>CDK1, ESR1, HSP90A11, and MAPK1 were shown to be the key targets of <em>P. cuspidatum</em> for hepatocellular carcinoma. <em>P. cuspidatum</em> was found to be likely correlated with the improved abnormal expression of CDK1 and ESR1 and the poor prognosis of HSP90AA1 and MAPK1. CDK1 was identified as the most potential anti-hepatocellular carcinoma target of <em>P. cuspidatum</em>. Among the active components of <em>P. cuspidatum</em>, physcion diglucoside was found to have the most potential to treat hepatocellular carcinoma by targeting CDK1.</p></div><div><h3>Conclusion</h3><p>Our study provides novel insights into the anti-hepatocellular carcinoma pharmacological effects of <em>P. cuspidatum</em>, which could serve as a scientific basis for its development as a medicinal resource and the targeting of CDK1 for hepatocellular carcinoma treatment.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 3","pages":"Article 100115"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000409/pdfft?md5=11fd39f142c9e35b0e9dd563005a3e5a&pid=1-s2.0-S2772947824000409-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142172692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor burden score and alpha-fetoprotein level predict prognosis of patients with unresectable hepatocellular carcinoma treated with tyrosine kinase inhibitor and anti-PD-1 antibody","authors":"Shichuan Tang ,&nbsp;Tingfeng Huang ,&nbsp;Cong Luo ,&nbsp;Jun Fu ,&nbsp;Kailing Zhang ,&nbsp;Qingjing Chen ,&nbsp;Jie Kong ,&nbsp;Jianxi Zhang ,&nbsp;Zhenghong Sun ,&nbsp;Yongkang Diao ,&nbsp;Kongying Lin ,&nbsp;Yongyi Zeng","doi":"10.1016/j.iliver.2024.100109","DOIUrl":"10.1016/j.iliver.2024.100109","url":null,"abstract":"<div><h3>Background</h3><p>Tyrosine kinase inhibitors (TKIs) and anti-PD-1 antibodies in combination provide survival benefits for patients with unresectable hepatocellular carcinoma (uHCC). However, the tool used to determine which patients likely benefit most from this treatment strategy has not been reported. We sought to develop a prognostic scoring system based on tumor burden score (TBS) and alpha-fetoprotein (AFP) to predict the long-term prognosis of uHCC treated with TKIs and anti-PD-1 antibodies.</p></div><div><h3>Methods</h3><p>Data on patients with uHCC treated with TKIs and anti-PD-1 antibodies from multiple centers were collected. The prognostic accuracy of TBS, AFP, Barcelona Clinic Liver Cancer (BCLC), and CTA (Combined TBS and AFP) for 2-year progression-free survival (PFS) and overall survival (OS) was evaluated.</p></div><div><h3>Results</h3><p>Overall, 278 patients with uHCC treated with TKIs and anti-PD-1 antibodies were enrolled, including 48 BCLC-B and 230 BCLC-C HCC patients. CTA (AUC = 0.721 and 0.683) outperformed TBS (AUC = 0.680 and 0.621), AFP (AUC = 0.606 and 0.594), and BCLC staging (AUC = 0.551 and 0.555) in predicting PFS and OS. The 2-year PFS and OS for low CTA (low TBS/low AFP) were 65.7% and 94.4%, respectively, which were significantly higher than 21.6% and 44.9% (<em>p</em> &lt; 0.001 and <em>p</em> = 0.002), respectively, for intermediate CTA (low TBS/high AFP or high TBS/low AFP) and 8.7% and 12.1% (both <em>p</em> &lt; 0.001), respectively, for high CTA (high TBS/high AFP). Multivariable Cox regression analysis indicated that CTA grading was an independent prognostic factor for PFS and OS (referent: low CTA; intermediate CTA, HR 2.87 and 7.17; high CTA, HR 5.52 and 10.31, respectively).</p></div><div><h3>Conclusions</h3><p>CTA grading is an accurate tool for stratifying the prognosis of uHCC treated with TKIs and anti-PD-1 antibodies and may help determine which patients may benefit more from this treatment strategy.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 3","pages":"Article 100109"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000343/pdfft?md5=6af753a448301ae70ed3eddae4d63605&pid=1-s2.0-S2772947824000343-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142040260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transarterial chemoembolization plus radiofrequency ablation: One of the effective interventions for hepatocellular carcinoma","authors":"Yong Xie,&nbsp;Jian Wang,&nbsp;Yinghua Zou","doi":"10.1016/j.iliver.2024.100114","DOIUrl":"10.1016/j.iliver.2024.100114","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 3","pages":"Article 100114"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000392/pdfft?md5=872f44ce832e9d7fb0cf35da0ff3d221&pid=1-s2.0-S2772947824000392-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142172767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting hepatocellular carcinoma growth and metabolism: A synergistic approach with para-toluenesulfonamide and radiofrequency ablation","authors":"Na Liu ,&nbsp;Jianzeng Zhang ,&nbsp;Jiaojiao Wu ,&nbsp;Fan Feng ,&nbsp;Yantao Chai ,&nbsp;Yongwu Li ,&nbsp;Bo Liu","doi":"10.1016/j.iliver.2024.100111","DOIUrl":"10.1016/j.iliver.2024.100111","url":null,"abstract":"<div><h3>Background and aims</h3><p>Hepatocellular carcinoma (HCC) is one of the most prevalent and lethal forms of cancer, posing challenges to standard treatment methods. Radiofrequency ablation (RFA) has emerged as a valuable technique for the local control of advanced HCC, especially in cases unsuitable for surgical resection. Para-toluenesulfonamide (PTS) has demonstrated antitumor properties in various cancers, yet its efficacy against HCC remains underexplored. The present study aims to investigate the therapeutic potential of PTS in HCC and examine potential synergistic effects with RFA.</p></div><div><h3>Methods</h3><p>PTS was injected directly into subcutaneous tumor tissues and its effects on cell survival, gene expression, and metabolic activity in HCC cells were evaluated. The effect of PTS and RFA in combination on HCC growth was examined using a nude mouse model of subcutaneous HCC. Data were visualized using heat maps.</p></div><div><h3>Results</h3><p>PTS inhibited the survival of HCC cells in a dose-dependent manner, modulating the expression of key genes related to cell survival, apoptosis, epithelial–mesenchymal transition, and proliferation. The combination of PTS and RFA markedly enhanced the inhibition of HCC tumor growth and induced alterations in cellular metabolism.</p></div><div><h3>Conclusion</h3><p>Combining PTS and RFA may be a promising approach to improve the efficacy of HCC treatment.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 3","pages":"Article 100111"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000367/pdfft?md5=b0e8499504bb732be1b53d5b3ef270e3&pid=1-s2.0-S2772947824000367-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142098567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}